BioScrip Company Profile (NASDAQ:BIOS)

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Health Care
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BIOS
  • CUSIP: 09069N10
  • Web:
  • Market Cap: $208.09 million
  • Outstanding Shares: 120,982,000
Average Prices:
  • 50 Day Moving Avg: $1.57
  • 200 Day Moving Avg: $1.52
  • 52 Week Range: $0.98 - $3.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.82
  • P/E Growth: -0.390
Sales & Book Value:
  • Annual Revenue: $914.94 million
  • Price / Sales: 0.23
  • Book Value: ($0.40) per share
  • Price / Book: -4.30
  • EBIDTA: $25.34 million
  • Net Margins: -5.18%
  • Return on Assets: -5.82%
  • Debt-to-Equity Ratio: -15.98%
  • Current Ratio: 1.13%
  • Quick Ratio: 0.89%
  • Average Volume: 2.03 million shs.
  • Beta: 0.6
  • Short Ratio: 5.79

Frequently Asked Questions for BioScrip (NASDAQ:BIOS)

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $217.80 million for the quarter, compared to analyst estimates of $230.23 million. The firm's revenue for the quarter was down 8.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. View BioScrip's Earnings History.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?

3 brokerages have issued 12 month price targets for BioScrip's stock. Their forecasts range from $2.25 to $4.50. On average, they expect BioScrip's stock price to reach $3.25 in the next year. View Analyst Ratings for BioScrip.

What are analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "BioScrip posted a dull first quarter, with earnings and sales missing the Zacks Consensus Estimate. The year-over-year drop in revenues in the first quarter was partly due to lower-than-expected core sales volumes. Management’s 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns. Reimbursement pressure and a tough competitive scenario continue to pose challenges. However, the dismal first-quarter performance has not affected the share price, which has been trading above the broader Medical Output/Homecare industry for majority of the last three months. We are encouraged by the company’s progress in the first quarter for its new multi-faceted CORE plan to improve its financial position. Further, BioScrip successfully completed the Home Solutions’ integration within the first quarter." (5/10/2017)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Are investors shorting BioScrip?

BioScrip saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 18,221,448 shares, an increase of 1.7% from the April 13th total of 17,916,164 shares. Based on an average trading volume of 984,865 shares, the days-to-cover ratio is currently 18.5 days.

Who are some of BioScrip's key competitors?

Who owns BioScrip stock?

BioScrip's stock is owned by a number of of institutional and retail investors. Top institutional investors include GAMCO INVESTORS, INC. ET AL (11.76%), Gabelli Funds LLC (10.23%), Camber Capital Management LLC (8.41%), Coliseum Capital Management LLC (4.65%), Diamond Hill Capital Management Inc. (4.26%) and FMR LLC (3.97%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Institutional Ownership Trends for BioScrip.

Who sold BioScrip stock? Who is selling BioScrip stock?

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Gabelli Funds LLC, Dimensional Fund Advisors LP, Gamco Investors INC. ET AL, Diamond Hill Capital Management Inc., Eidelman Virant Capital, Morgan Stanley and Vanguard Group Inc.. View Insider Buying and Selling for BioScrip.

Who bought BioScrip stock? Who is buying BioScrip stock?

BioScrip's stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, FMR LLC, California Public Employees Retirement System, KCG Holdings Inc., Geode Capital Management LLC, Wynnefield Capital Inc., Citadel Advisors LLC and Alambic Investment Management L.P.. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Insider Buying and Selling for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioScrip stock cost?

One share of BioScrip stock can currently be purchased for approximately $1.72.

Analyst Ratings

Consensus Ratings for BioScrip (NASDAQ:BIOS) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.25 (88.95% upside)

Analysts' Ratings History for BioScrip (NASDAQ:BIOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/6/2017Barrington ResearchBoost Price TargetOutperform -> Outperform$1.50 -> $2.25N/AView Rating Details
3/6/2017Jefferies Group LLCBoost Price TargetBuy$2.50 -> $3.00N/AView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
8/12/2015Dougherty & CoLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
8/11/2015SunTrust Banks, Inc.DowngradeBuy -> Neutral$5.00 -> $2.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for BioScrip (NASDAQ:BIOS)
Earnings by Quarter for BioScrip (NASDAQ:BIOS)
Earnings History by Quarter for BioScrip (NASDAQ:BIOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioScrip (NASDAQ:BIOS)
2017 EPS Consensus Estimate: ($0.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.14)($0.08)($0.12)
Q2 20172($0.10)($0.06)($0.08)
Q3 20173($0.08)($0.04)($0.06)
Q4 20173($0.05)$0.00($0.02)
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for BioScrip (NASDAQ:BIOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioScrip (NASDAQ:BIOS)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 82.02%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.00View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.00View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.00View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.00View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.00View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.00View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.00View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.00View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.78View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioScrip (NASDAQ:BIOS)
Latest Headlines for BioScrip (NASDAQ:BIOS)
DateHeadline logoShort Interest in BioScrip Inc (BIOS) Expands By 1.7% - May 13 at 7:08 PM logoDull Q1 Earnings & Tough Industry Spell Trouble for BioScrip - Nasdaq - May 12 at 9:32 PM logo$219.72 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter - May 12 at 4:52 PM logoETFs with exposure to BioScrip, Inc. : May 11, 2017 - May 11 at 4:28 PM logoZacks Investment Research Downgrades BioScrip Inc (BIOS) to Sell - May 10 at 1:34 PM logoZacks: Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.09 Per Share - May 10 at 8:16 AM logoBioScrip, Inc. :BIOS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:56 PM logoBRIEF-Bioscrip reports first quarter 2017 financial results - May 6 at 1:58 AM logoBioScrip Inc (BIOS) Posts Earnings Results, Misses Estimates By $0.04 EPS - May 5 at 5:44 PM logoBioScrip Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 5 at 3:56 PM logoForm 4 BioScrip, Inc. For: May 02 Filed by: Coliseum Capital Management, LLC - - May 5 at 3:56 PM logoBioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss - Nasdaq - May 5 at 3:56 PM logoEdited Transcript of BIOS earnings conference call or presentation 4-May-17 1:00pm GMT - May 5 at 2:06 AM logoInvestor Network: BioScrip, Inc. to Host Earnings Call - May 4 at 4:03 PM logoBioScrip Reports First Quarter 2017 Financial Results - May 4 at 4:03 PM logoBioScrip reports 1Q loss - May 4 at 4:03 PM logoSomewhat Favorable News Coverage Likely to Impact BioScrip (BIOS) Stock Price - May 3 at 5:22 PM logoBioScrip Inc (BIOS) Set to Announce Quarterly Earnings on Thursday - May 2 at 11:24 AM logoBioScrip (BIOS) Getting Somewhat Negative Media Coverage, Report Finds - April 29 at 5:27 PM logoBioScrip (BIOS) Earns Daily Coverage Optimism Rating of 0.20 - April 26 at 7:02 PM logoHow a ‘Christmas miracle’ became a nightmare for heart-failure patients - April 25 at 12:37 PM logoBioScrip (BIOS) Earning Favorable News Coverage, Study Finds - April 23 at 1:23 PM logoBioScrip Announces CFO Transition - GlobeNewswire (press release) - April 20 at 9:02 PM logoBioScrip (BIOS) Earning Somewhat Critical Media Coverage, Report Shows - April 20 at 4:39 PM logoBioScrip Announces CFO Transition - April 20 at 4:02 PM logo Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.12 EPS - April 19 at 7:33 AM logoBioScrip To Host First Quarter 2017 Results Call - GlobeNewswire (press release) - April 18 at 3:51 PM logoSomewhat Favorable News Coverage Extremely Likely to Impact BioScrip (BIOS) Stock Price - April 17 at 5:25 PM logoBioScrip To Host First Quarter 2017 Results Call - April 17 at 9:46 AM logoBioScrip (BIOS) Getting Somewhat Favorable Press Coverage, Report Shows - April 14 at 5:59 PM logoBioScrip Inc (BIOS) Short Interest Down 8.0% in March - April 14 at 7:34 AM logoWhy Is BioScrip (BIOS) Up 18.5% Since the Last Earnings Report? - April 3 at 4:19 PM logoJefferies Group Comments on BioScrip Inc's Q1 2017 Earnings (BIOS) - April 3 at 8:38 AM logoQ1 2017 EPS Estimates for BioScrip Inc Reduced by SunTrust Banks (BIOS) - April 3 at 8:38 AM logoForm 8-K BioScrip, Inc. For: Mar 27 - - March 29 at 4:14 PM logoBioScrip Announces Meeting with Investors - March 27 at 11:10 AM logoBIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 27 at 11:10 AM logo9:03 am Bioscrip reaffirms FY17 adj. EBITDA; expects improved profitability following termination of agreement with UnitedHealthcare - March 27 at 11:10 AM logoBIOSCRIP, INC. Financials - March 11 at 3:51 PM logoBarrington Research Boosts BioScrip Inc (BIOS) Price Target to $2.25 - March 10 at 9:03 AM logoBiocon Chairman Says Stock Price Warranted on Pipeline - March 8 at 4:40 PM logoBiocon Chairman Says Stock Price Warranted on Pipeline - March 8 at 4:40 PM logoBIOSCRIP, INC. Files SEC form 10-K, Annual Report - March 7 at 8:57 PM logoJefferies boosts price target on BioScrip; shares ahead 20% - Seeking Alpha - March 7 at 5:11 AM logoBiotech's Rally in 2017 Gaining Steam After President Trump's Speech: Today's Reports on BioScrip and Novavax - March 6 at 10:52 AM logoCompany News for March 06, 2017 - March 6 at 10:52 AM logoBioScrip Inc (BIOS) Hikes on Strong Q4 Results - March 5 at 9:15 AM logoMid-Day Market Update: Nutanix Drops On Weak Guidance; BioScrip Shares Climb - Benzinga - March 4 at 4:26 PM logoEarnings Reaction History: BioScrip, Inc., 75.0% Follow-Through Indicator, 16.1% Sensitive - Nasdaq - March 4 at 4:26 PM logoBRIEF-Bioscrip Q4 loss per share $0.06 - March 4 at 2:12 AM



BioScrip (BIOS) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff